Edit
Forty Seven
http://fortyseveninc.com/Last activity: 21.03.2020
Active - Reference to Gilead Sciences
With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.
Total raised: $156M
Investors 3
| Date | Name | Website |
| - | Lightspeed... | lsvp.com |
| - | BlueBird V... | bluebirdvc... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.08.2019 | - | $6M | - |
| 18.10.2017 | Series B | $75M | - |
| 25.02.2016 | Series A | $75M | - |
Mentions in press and media 20
| Date | Title | Description |
| 21.03.2020 | Gilead To Buy Forty Seven, for $4.9 Billion | Gilead Sciences, Inc. (Nasdaq: GILD) is to acquire Forty Seven, Inc. (Nasdaq: FTSV), a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based... |
| 02.03.2020 | Gilead to buy cancer immunotherapy company Forty Seven for $4.9B | Forty Seven’s lead product candidate is magrolimab, a monoclonal antibody targeting the cell-surface protein CD47 in Phase Ib development for blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and diffuse large ... |
| 12.02.2020 | ALX Oncology raises $105M in Series C round for checkpoint inhibitor development | The company plans to invest the money in its lead drug candidate, ALX148, a CD47-targeting checkpoint inhibitor that it is developing in combination with other therapies in solid tumors and blood cancers. The drug is designed to maximize th... |
| 07.08.2019 | Forty Seven Raises $6M in Funding | Forty Seven, Inc., a Menlo Park, CA-based clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, received $6m in funding. The Leukemia & Lymphoma Society (LLS) provid... |
| 26.03.2019 | Arch Oncology raises $50M in Series B round for Phase I CD47-targeting antibody | The financing was led by a new investor, Lightchain – the family office of Scottrade founder and former CEO Rodger Riney – with participation from existing investors RiverVest Venture Partners, Roche Venture Fund and 3×5 Partners. Another c... |
| 28.06.2018 | Term Sheet — Thursday, June 28 | LYFTED Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop Here are some additional notes: • In total, Lyft has raised $5.1 billion in funding. Lyft’s investors include AllianceBernstein, Baillie... |
| 19.06.2018 | Term Sheet — Tuesday, June 19 | MORE DATA, FEWER HUMANS What’s going on at venture firm Social Capital is less of a shake-up and more of an upheaval. Paid Content Securing the enterprise without boundaries From ExtraHop It’s unclear what Bates and Mezvinsky will do next, ... |
| 20.10.2017 | Term Sheet — Friday, October 20 | TRENDY IPO Happy Friday, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Stitch Fix has been hyper-focused on profitability in fiscal year 2017. The company increased its revenue 13-fold since 2014 ... |
| 18.10.2017 | Forty Seven Closes $75M Series B Financing | Forty Seven Inc., a Menlo Park, CA-based clinical-stage immuno-oncology company, raised a $75m Series B funding. The round was led by new investor Wellington Management Company LLP with participation from existing investors Clarus, Lightspe... |
| 18.10.2017 | Forty Seven raises another $75M to expand I-O trial slate W h i t e p a p e r Weighing the Costs: | Forty Seven has raised $75 million, bringing its total haul to date up to $150 million. The series B round equips the Stanford University spinout to expand trials of its CD47-targeted approach to dialing up phagocytosis of cancer cells. Spo... |
Show more